Chitinase-3-like protein 1 (YKL-40): novel biomarker of lichen planus.

Int J Dermatol

Lecturer of Clinical Pathology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt.

Published: September 2019

Background: Lichen planus (LP) is an inflammatory skin disorder of unknown etiology. Chitinase-3-like protein 1 (YKL-40) is a multifunctional proinflammatory protein, which has an important role not only in immunity and inflammation, but also in the regulation of cell proliferation, differentiation, and apoptosis.

Aim Of The Work: The present study was designed to investigate the serum level of YKL-40 in patients with different clinical presentations of LP in comparison to healthy participants in order to study its possible role in the pathogenesis of LP.

Patients And Methods: A total of 60 consecutive subjects were enrolled in this prospective case-control study including 30 patients with different clinical variants of LP (16 male and 14 female patients) in addition to 30 healthy controls matched for age and gender. The serum level of serum YKL-40 was evaluated by means of ELISA method in both patients and controls.

Results: The serum YKL-40 level was significantly higher (P < 0.001) in patients than in controls. Also, significantly higher levels were found in patients with oral type than in patients with cutaneous type who do not have oral lesions (P < 0.05). The sensitivity and specificity of serum YKL-40 were 62.5 and 81.8%, respectively, (cut off value of 151 pg/ml) for the diagnosis of oral lesions in LP.

Conclusion: The findings in our study support the role of YKL-40 in the pathogenic process of LP and may help in treatment of lichen planus.

Download full-text PDF

Source
http://dx.doi.org/10.1111/ijd.14551DOI Listing

Publication Analysis

Top Keywords

chitinase-3-like protein
8
protein ykl-40
8
lichen planus
8
serum level
8
patients clinical
8
serum ykl-40
8
ykl-40
5
ykl-40 novel
4
novel biomarker
4
biomarker lichen
4

Similar Publications

Chitinase-3-like-1 (Chi3l1), also known as YKL-40 or BRP-39, is a highly conserved mammalian chitinase with a chitin-binding ability but no chitinase enzymatic activity. Chi3l1 is secreted by various cell types and induced by several inflammatory cytokines. It can mediate a series of cell biological processes, such as proliferation, apoptosis, migration, differentiation, and polarization.

View Article and Find Full Text PDF

Multiple sclerosis (MS) is a chronic demyelinating disease of the central nervous system (CNS) with a complex and not fully understood etiopathological background involving inflammatory and neurodegenerative processes. CHI3L1 has been implicated in pathological conditions such as inflammation, injury, and neurodegeneration, and is likely to play a role in the physiological development of the CNS. CHI3L1 is primarily produced by CNS macrophages, microglia, and activated astrocytes.

View Article and Find Full Text PDF

Background: Oesophageal cancer (EC) is one of the common malignant tumors, and the prognosis of patients is poor. Further exploration of EC pathogenesis remains warranted.

Objective: The relationship between vascular epithelial cadherin (VE-cadherin) and chitinase-3-like protein 1 (CHI3L1) in EC is currently unknown.

View Article and Find Full Text PDF

Background And Objectives: Blood-based biomarkers of amyloid and tau have been shown to predict Alzheimer disease (AD) dementia. Much less is known about their ability to predict risk of mild cognitive impairment (MCI), an earlier disease stage. This study examined whether levels of blood biomarkers of amyloid (Aβ/Aβ ratio), tau (p-tau), neurodegeneration (NfL), and glial activation and neuroinflammation (glial fibrillary acidic protein [GFAP], YKL40, soluble triggering receptor expressed on myeloid cells 2 [sTREM2]) collected when participants were cognitively normal are associated with the time to onset of MCI.

View Article and Find Full Text PDF

Aims: We investigated the association of the inflammatory biomarker YKL-40 with cardiovascular events (CVEs) and mortality in individuals with type 2 diabetes.

Methods: We followed 11,346 individuals recently diagnosed with type 2 diabetes for up to 14 years. Baseline YKL-40 levels (measured in 9,010 individuals) were grouped into percentiles (0-33 %, 34-66 %, 67-90 %, and 91-100 %) and analyzed continuously (per 1 SD log increment), with comparisons to CRP (measured in 9,644 individuals).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!